Orchard Therapeutics plc - ADR

NASDAQ:ORTX  
4.87
+0.17 (+3.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)620.73M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.56 Million
Adjusted EPS-$0.31
See more estimates
10-Day MA$4.97
50-Day MA$5.56
200-Day MA$5.67
See more pivots

Orchard Therapeutics plc - ADR Stock, NASDAQ:ORTX

108 Cannon Street, London, Greater London EC4N 6EU
Phone: +44.20.3808.8286
Number of Employees: 224

Description

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.